Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 43 Presentations at the 74th American Diabetes Association Scientific Sessions

More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company diabetes portfolio at the 74th American Diabetes Association (ADA) Scientific Sessions in San Francisco, June 13–17. The commitment of the BI-Lilly Diabetes alliance to the care of adults with diabetes is exemplified by a focus on compounds representing several of the largest diabetes treatment classes. 

LY2963016, Investigational New Insulin Glargine Product Data

A total of six clinical abstracts for the investigational basal (long-acting) insulin LY2963016, new insulin glargine product, will be presented. LY2963016 is a new insulin glargine product being developed for the treatment of patients with type 1 and type 2 diabetes.

Details of all clinical presentations and posters are as follows:

Saturday, 14 June, 8:00 - 10:00 a.m. PT, Oral Presentation - Basal Insulin Therapy
• Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2D: the ELEMENT 2 Study (Presenting Author: J. Rosenstock) [Oral No. 64-OR]
• Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1D: the ELEMENT 1 Study (Presenting Author: T. Blevins) [Oral No. 69-OR]
• Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1D or T2D (Presenting Author: M. Deeg) [Oral No. 70-OR]

Saturday, 14 June, 11:30 a.m. - 1:30 p.m. PT, General Poster Session
• Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and US-approved Versions of Lantus Insulin Glargine in Healthy Subjects (Presenting Author: H. Linnebjerg) [Poster No. 889-P]
• Comparative Pharmacokinetics and Pharmacodynamics of Two Insulin Glargine Products, LY2963016 and Lantus, in Healthy Subjects at Two Dose Levels (Presenting Author: X. Zhang) [Poster No. 890-P]
• Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus, in Subjects with Type 1 Diabetes Mellitus (T1DM) (Presenting Author: T. Heise) [Poster No. 891-P]
Posters 889-P, 890-P and 891-P will also be featured in a guided audio poster tour on Monday 16 June, 1:00 - 1:50 p.m. PT, titled "Pharmacokinetic/Pharmacodynamic Insulin Studies."

Posters 889-P, 890-P and 891-P will also be featured in a guided audio poster tour on Monday 16 June, 1:00 - 1:50 p.m. PT, titled "Pharmacokinetic/Pharmacodynamic Insulin Studies."